Neuroleptic Malignant Syndrome: Next-Line Treatment After Initial Supportive Critical Care Has Not Controlled Muscular Signs
When initial management of neuroleptic malignant syndrome has not brought muscular signs under control or has failed to maintain target euvolemia, a defined next-line pharmacological protocol is indicated.
Prior Treatment — What Was Tried First
The first-line protocol involves withdrawal of the offending dopamine-blocking agent, high-volume intravenous saline infusion to maintain euvolemia and manage rhabdomyolysis, antipyretics and evaporative cooling for hyperthermia, and lorazepam for mild muscular rigidity.
Failure condition: The target of maintaining euvolemia — urine output of approximately 200 to 300 ml per hour — was not achieved, and muscular signs persisted or worsened despite these measures.
Next-Line Approach (partial overview)
When muscular signs persist or worsen, the protocol calls for a specific pharmacological agent that acts directly on skeletal muscle through a mechanism at the sarcoplasmic reticulum, with alternative agents from a dopaminergic class available when indicated. The complete selection criteria, sequencing, and full regimen are contained in the structured protocol.
Clinical Goals
- Reduction of muscular rigidity
- Mitigation of hyperthermia
- Reduction of elevated serum creatine kinase
References
DOI: 10.1056/NEJMra2404606
- However, if muscular signs of neuroleptic malignant syndrome persist or worsen, dantrolene, a direct-acting skeletal-muscle relaxant that inhibits the release of calcium at the sarcoplasmic reticulum, can be administered.
- By reducing rigidity and through ostensible effects on central thermoregulatory areas, dantrolene mitigates hyperthermia and reduces elevated levels of serum creatine kinase.
- Bromocriptine or amantadine has been suggested as an alternative agent; both are dopamine agonists that displace antipsychotic dopamine antagonists and are associated with few short-term side effects.
- These specific dopaminergic interventions are usually justified when the core temperature reaches 38 to 40°C and rigidity is moderate or severe, as marked by a transition from palpably mild rigidity with cogwheeling to sustained rigidity.
View source ↗